Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLG | P00747 | 2/20 | 0.46 |
| ▸ | PLAU | P00749 | 2/20 | 0.46 |
| ▸ | KRAS | P01116 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | CDK4 | P11802 | 2/20 | 0.43 |
| ▸ | CCND1 | P24385 | 2/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | GLS | O94925 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29167245 | 0.89 | MAPT (0.51) | PLGPLAUKRASPOLBMAPT | |
| SCHEMBL30785020 | 0.89 | MAPT (0.51) | PLGPLAUKRASPOLBMAPT | |
| SCHEMBL12475241 | 0.86 | HTR7 (0.52) | PLGPLAUKRASPOLBMAPT | |
| SCHEMBL10430002 | 0.85 | PLG (0.46) | PLGPLAUKRASCDK4CCND1 | |
| SCHEMBL14404541 | 0.85 | PLG (0.44) | PLGPLAUKRASCDK4CCND1 | |
| SCHEMBL7921048 | 0.84 | KRAS (0.47) | PLGPLAUKRASHTR7 | |
| SCHEMBL23902730 | 0.83 | GLS (0.46) | PLGPLAUKRASCDK4CCND1 | |
| SCHEMBL2263041 | 0.83 | GLS (0.46) | PLGPLAUKRASCDK4CCND1 | |
| SCHEMBL2479169 | 0.83 | HTR7 (0.47) | PLGPLAUKRASMAPTHTR7 | |
| SCHEMBL7798236 | 0.83 | HTR7 (0.56) | PLGPLAUPOLBMAPTATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063758-A1 | INHIBITORS OF BACTERIAL NAD SYNTHETASE | BROUILLETTE WAYNE J (US) | 2004-04-01 | — | — | US | claimed |
| JP-2002509149-A | — | — | 2002-03-26 | — | — | JP | claimed |
| EP-1109805-A1 | INHIBITORS OF BACTERIAL NAD SYNTHETASE | The UAB Research Foundation (US) | 2001-06-27 | — | — | EP | claimed |
| EP-1047692-A1 | METHODS OF SYNTHESIZING AND SCREENING INHIBITORS OF BACTERIAL NAD SYNTHETASE ENZYME, COMPOUNDS THEREOF AND METHODS OF TREATING BACTERIAL AND MICROBIAL INFECTIONS WITH THESE INHIBITORS | THE UAB RESEARCH FOUNDATION (US) | 2000-11-02 | — | — | EP | claimed |
| WO-2000010996-A1 | INHIBITORS OF BACTERIAL NAD SYNTHETASE | THE UAB RESEARCH FOUNDATION (US) | 2000-03-02 | — | — | WO | claimed |
| WO-1999036422-A1 | METHODS OF SYNTHESIZING AND SCREENING INHIBITORS OF BACTERIAL NAD SYNTHETASE ENZYME, COMPOUNDS THEREOF, AND METHODS OF TREATING BACTERIAL AND MICROBIAL INFECTIONS WITH INHIBITORS OF BACTERIAL NAD SYNTHETASE ENZYME | THE UAB RESEARCH FOUNDATION (US) | 1999-07-22 | — | — | WO | claimed |
| WO-2005002337-A1 | DISINFECTANT COMPOSITIONS AND METHODS | VIRTUAL DRUG DEVELOPMENT, INC. (US) | 2005-01-13 | — | — | WO | disclosed |
| EP-1047692-B1 | METHODS OF SYNTHESIZING AND SCREENING INHIBITORS OF BACTERIAL NAD SYNTHETASE ENZYME, COMPOUNDS THEREOF AND METHODS OF TREATING BACTERIAL AND MICROBIAL INFECTIONS WITH THESE INHIBITORS | UAB RESEARCH FOUNDATION (US) | 2004-07-21 | — | — | EP | disclosed |
| US-6727237-B2 | Inhibitors of bacterial NAD synthetase | BROUILLETTE WAYNE J (US) | 2004-04-27 | — | — | US | disclosed |
| US-20040063758-A1 | INHIBITORS OF BACTERIAL NAD SYNTHETASE | BROUILLETTE WAYNE J (US) | 2004-04-01 | — | — | US | disclosed |
| US-6500852-B1 | ENZYME INHIBITORS OF BACTERIAL NICOTINAMIDE ADENINE DINUCLEOTIDE (NAD) ENZYME LYASES USED AS BACTERICIDES, MICROBIOCIDE, ANTISEPTICS OR ANTIBIOTICS | UNIVERSITY OF ALABAMA RESEARCH FOUNDATION | 2002-12-31 | — | — | US | disclosed |
| EP-1109805-A1 | INHIBITORS OF BACTERIAL NAD SYNTHETASE | The UAB Research Foundation (US) | 2001-06-27 | — | — | EP | disclosed |
| EP-1047692-A1 | METHODS OF SYNTHESIZING AND SCREENING INHIBITORS OF BACTERIAL NAD SYNTHETASE ENZYME, COMPOUNDS THEREOF AND METHODS OF TREATING BACTERIAL AND MICROBIAL INFECTIONS WITH THESE INHIBITORS | THE UAB RESEARCH FOUNDATION (US) | 2000-11-02 | — | — | EP | disclosed |
| WO-2000010996-A1 | INHIBITORS OF BACTERIAL NAD SYNTHETASE | THE UAB RESEARCH FOUNDATION (US) | 2000-03-02 | — | — | WO | disclosed |
| WO-1999036422-A1 | METHODS OF SYNTHESIZING AND SCREENING INHIBITORS OF BACTERIAL NAD SYNTHETASE ENZYME, COMPOUNDS THEREOF, AND METHODS OF TREATING BACTERIAL AND MICROBIAL INFECTIONS WITH INHIBITORS OF BACTERIAL NAD SYNTHETASE ENZYME | THE UAB RESEARCH FOUNDATION (US) | 1999-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063758-A1 | INHIBITORS OF BACTERIAL NAD SYNTHETASE | COASY, NADK, NQO1 | PLG 2916/4885PLAU 2063/4885KRAS 2434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.